SUWANEE, GA–(Marketwired – Feb 23, 2017) – SANUWAVE Health, Inc. ( OTCQB : SNWV ) announces the launch of the blog, SHOCK THIS on its website www.sanuwave.com. The initial post will be from SANUWAVE’s head of Research and Development, Dr. Iulian Cioanta, titled “What is a shockwave.” The goal of the blog is to allow a medium to help educate customers, patients, partners, and the public about the various initiatives under way at SANUWAVE. The blog will also accept posts and comments (approved by SANUWAVE), which the Company views as valuable to the SANUWAVE community. This is expected to be a constructive forum for users from around the globe. By having a central location, SHOCK THIS, the Company can bring together in one setting various information that will be useful and entertaining to the SANUWAVE community. The initial blog is meant to help people understand, what is a shock wave. Many misconceptions exist about the technology, what it is and what it isn’t, so the plan is to help expand people’s understanding by educating in a fun manner. Members of the SANUWAVE community are encouraged to interact and reach out with thoughts and ideas, which will positively impact the SANUWAVE community as a whole. SANUWAVE Health, Inc. reserves the right to edit or exclude comments it deems not positively impacting the experience or is not appropriate from legal and regulatory perspectives. Kevin Richardson, SANUWAVE’s Acting CEO, said, “This is an exciting launch for us as SANUWAVE begins the process of educating the market on the Company’s technology and devices’ capabilities. In the hopes of receiving FDA approval in the future, this is a first step in building SANUWAVE brand awareness.”

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.

BELGRADE, Mont., Feb. 22, 2017 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as the permanent CEO, effective February 17th, 2017. Mr. O’Connell previously served as president of Xtant since October of 2016 and was appointed as interim CEO on January 21st, 2017.

Prior to joining Xtant Medical, Mr. O’Connell most recently served as the Vice President Global Marketing – Extremities for Wright Medical, a recognized leader in the global foot and ankle market. Mr. O’Connell lead marketing teams and initiatives that were instrumental in achieving US growth initiatives that exceeded 28%, and 23% globally. He also lead the completion of marketing integration of 3 acquired businesses within a year, recruited top talent to his team, and supported the launch of multiple product line extensions and new products, including the successful launch of the market leading Infinity Total Ankle. During his tenure as Global Vice President Marketing for Stryker Spine, Mr. O’Connell drove marketing leadership and brand differentiation programs to support a 20% growth imperative, which was achieved through strategic cross divisional collaboration and the successful launches of line extensions and product upgrades. Mr. O’Connell served as the President and CEO of MedSurg – ITOCHU International, a division of ITOCHU Corporation, the 3rd largest Japanese trading corporation with over $70B in sales transactions, where he was responsible for the reorganization of three recently impaired acquisitions by supporting success attributes, acquiring new vendor contracts, stabilizing and growing top line sales at double digit growth rates, and driving the division to profitability.

“We are proud to announce Carl O’Connell has been promoted to the position of CEO” said Kent Swanson, Chairman of Xtant Medical’s Board of Directors. “With his extensive leadership in the medical device industry and commercialization expertise, we are confident that he is the right choice to lead Xtant to new levels of growth and profitability. Since joining the organization as President in 2016, he has made significant contributions to the record performance of the Company in Q4 2016 and we share his enthusiasm for the outlook of the Company.”

“I am excited to lead what I feel has the potential to be a world-class organization and a considerable competitor in the market” said Carl O’Connell, now CEO of Xtant Medical. “Since joining the organization, I have had a chance to assess the talented Xtant Medical team, the quality of our products, the commitment to our customers, the respect for the gift of donation, and the opportunity that lies ahead. I look forward to continuing to work with this team, expanding upon our recent successes and continuing to establish the strategic course to take Xtant Medical to the next level.  I am appreciative of the confidence bestowed in me by the executive management team, the board of directors, and our stakeholders.”

Carl O’Connell has over 30 years of experience in the healthcare and medical device arena. In addition to the positions held above, Mr. O’Connell also served as a Principal at Hudson Healthcare Partners, and President for Carl Zeiss Surgical, Inc. Mr. O’Connell’s responsibilities have spanned from global marketing, sales, manufacturing, leadership development, regulatory affairs, corporate quality systems, research, product and business development functions. Carl received a bachelor’s degree in Psychology and an M.B.A. from Mount St. Mary’s College, Maryland. Through the span of his career, Mr. O’Connell has launched more than 100 products and participated in numerous M&A events.

About Xtant Medical

Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

Important Cautions Regarding Forward-looking Statements

This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “continue,” “efforts,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “projects,” “forecasts,” “strategy,” “will,” “goal,” “target,” “prospects,” “potential,” “optimistic,” “confident,” “likely,” “probable” or similar expressions or the negative thereof.

Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: our ability to integrate the acquisition of X-spine Systems, Inc. and any other business combinations or acquisitions successfully; our ability to remain listed on the NYSE MKT; our ability to obtain financing on reasonable terms; our ability to increase revenue; our ability to comply with the covenants in our credit facility; our ability to maintain sufficient liquidity to fund our operations; the ability of our sales force to achieve expected results; our ability to remain competitive; government regulations; our ability to innovate and develop new products; our ability to obtain donor cadavers for our products; our ability to engage and retain qualified technical personnel and members of our management team; the availability of our facilities; government and third-party coverage and reimbursement for our products; our ability to obtain regulatory approvals; our ability to successfully integrate recent and future business combinations or acquisitions; our ability to use our net operating loss carry-forwards to offset future taxable income; our ability to deduct all or a portion of the interest payments on the notes for U.S. federal income tax purposes; our ability to service our debt; product liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; our ability to obtain and protect our intellectual property and proprietary rights; infringement and ownership of intellectual property; our ability to remain accredited with the American Association of Tissue Banks; influence by our management; our ability to pay dividends; our ability to issue preferred stock; and other factors.

Additional risk factors are listed in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading “Risk Factors.” You should carefully consider the trends, risks and uncertainties described in this document, the Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Investor Contact 
CG CAPITAL
Rich Cockrell 
877.889.1972
investorrelations@cg.capital 

Company Contact
Xtant Medical 
Molly Mason
mmason@xtantmedical.com

SUWANEE, GA–(Marketwired – Feb 21, 2017) – SANUWAVE Health, Inc. ( OTCQB : SNWV ) is pleased to announce the hiring of André Mouton to head the Company’s international sales and relations. SANUWAVE began a process 18 months ago of re-igniting their international efforts. This meant re-designing distribution agreements, restructuring partner economics, letting go of certain distributors, and adding new partners. The Company has also installed applicator refurbishment centers closer to the regions where the device is being used and this has had a strong acceptance among SANUWAVE’s customers. As SANUWAVE grows and expands on a country by country basis, the Company has found three models which work well for us: Distribution, Joint Ventures, and Exclusive Rights Agreements. Since the Company’s refocus on international sales the number of countries actively served has grown from 3 to 10, the number of device placements has tripled, and sales have increased as well.

Currently, SANUWAVE anticipates adding an additional 5 to 8 countries/regions in 2017. To assist in accelerating international growth and centralize the managing of the existing base the Company decided to bring on a senior level executive to streamline that process. SANUWAVE is pleased to announce André Mouton as the new VP of International Sales and Relations. André brings a strong history of growth and success in the healthcare community and deep relations globally. Kevin Richardson, SANUWAVE’s Acting CEO, stated, “André will allow us to manage and handle the massive growth and demand for SANUWAVE’s product internationally. His experience fits with the culture of solving the patients’ problems using shock wave technology.” André will also assist in the varied clinical work taking place internationally, which will in turn support all regions of the globe.

André has a background in Microbiology and obtained his MBA while working for a multi-national pharmaceutical group focusing on strategic marketing. He has resided in South Africa, Indonesia and Singapore and focused on business development and taking new products and services into the South East Asia (SEA) markets as well as Africa. He has held numerous senior positions with P&L responsibility as well as line management experience of staff of over 100 employees. He has assisted in numerous products entering new markets and was key to the process of adapting and entry strategy fit for local conditions and cultural acceptance.

André Mouton stated, “SANUWAVE is in a unique position to make a large impact on the global health community. The innovative dermaPACE^® product helps to solve a problem stemming from an unfortunate worldwide epidemic, diabetes. As I have traveled the globe, I have seen firsthand how diabetes is not just an American disease, and in fact, growth rates are even greater in developing countries. With the dermaPACE device SANUWAVE will help these patients live a happier healthier life.”

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE^®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron^® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron^® and orthoPACE^® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

EMMA NEWLANDS – 15 February 2017

Biomaterials business Collagen Solutions has revealed plans to raise up to £12 million and said it expects to reach profitability in 2019.

The Glasgow-based company, which develops and produces medical-grade collagen components for use in regenerative medicine, said the funding will reinforce its balance sheet, boosting confidence, speed up the progress of its core business and help develop new products.

It plans to raise up to about £8m in gross proceeds from current and new investors via a placing and open offer, subject to shareholder approval.

Furthermore, the Aim-quoted firm said it has received a conditional commitment from Norgine Ventures to subscribe up to £4m in secured private bonds with warrants.

Norgine Ventures is backed by European healthcare firm Norgine, and says it provides debt and debt-like funding to “innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US”.

Collagen Solutions said the net proceeds of the placing and open offer will go towards investment in the development and commercialisation of high-value device products, bring forward the launch of collagen-based implant ChondroMimetic, a key focus this year, and boost growth of its existing medical collagen supply business.

READ THE REST HERE

COLUMBIA, Md. , Feb. 10, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 7^th, 2017, confirmed the appointment of Messrs. Uwe Sommer and Thomas J. Knapp as Directors, upon recommendation of the Nominating Committee, and each will stand for election at the Company’s 2017 Stockholders’ Meeting.  Mr. Sommer and Mr. Knapp each join Osiris as independent Board members.

“We are pleased to have Mr. Sommer and Mr. Knapp join Osiris at this important time,” said Peter Friedli, Chairman of the Board. “Both gentlemen have extensive and diverse business experience, and their contributions will be greatly appreciated.”

Mr. Sommer is a highly experienced leader in global marketing and sales, managing distribution in markets including Europe, Japan, the Middle East, Africa, and the United States.  Mr. Sommer has held executive roles with Johnson & Johnson, Lindt & Sprüngli, Mars, Inc., and Procter & Gamble.  Mr. Sommer has degrees in Economics from University Kiel (Germany) and Marketing and Economics from Penn State University.

Mr. Knapp has over 25 years of corporate and large legal firm experience with regulated industries, with experience including Federal and State regulatory matters, Federal government affairs, risk management, compliance, litigation, complex commercial transactions, and corporate governance.  Mr. Knapp is presently Interim General Counsel and Corporate Secretary with Galena Biopharma, Inc., prior to which his experience includes serving as EVP, Chief Legal Officer, and Corporate Secretary of Sucampo Pharmaceuticals, Inc., as Vice President, General Counsel and Corporate Secretary at NorthWestern Corporation, and in senior in-house attorney positions at The Boeing Company and The Burlington Northern & Santa Fe Railway Company.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs.  Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field.  Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products.  Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO^4®, a viable bone matrix, Cartiform^®, a viable osteochondral allograft, Grafix^®, a cryopreserved placental membrane, and Stravix^®, a durable placental allograft.  Osiris, Grafix, Cartiform, and Stravix are trademarks of Osiris Therapeutics, Inc.  BIO⁴ is a registered trademark of Howmedica Osteonics Corp.  More information can be found on the company’s website, www.osiris.com. (OSIR-G)

For additional information, please contact:

Diane Savoie

Osiris Therapeutics, Inc.

(443) 545-1839

OsirisPR@Osiris.com

Source: Osiris Therapeutics, Inc.

News Provided by Acquire Media

READ THE REST HERE

January 28, 2017 – from Chuck Chiang

Patients who tear, rupture or otherwise damage cartilage or other bodily tissue may one day be able to simply go to the hospital and get a replacement, if new “3D bioprinting” technology being developed by a Vancouver firm reaches its full potential.

Aspect Biosystems, which was spun off from UBC research efforts in 2013, says the technology can create — or “print out” — human tissue within minutes, and could one day be able to provide “on-demand parts” for ailing patients.

Tamer Mohamed, Aspect’s CEO, said tissue creation for medical use will need to go through a long process of regulatory testing and certification before seeing the light of day, which he expects will take years. But he added that, if all goes well, patients could see the technology in certain clinical environments “in less than 10 years”.

He noted that Aspect’s recent announcement of a research deal with pharmaceutical giant Johnson & Johnson to create 3D-printed meniscus tissue as an example of how the technology could one day be used.

READ THE REST HERE

FREMONT, Calif., Feb. 3, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced the company is extending the expiration date of certain warrants. The decision to extend the warrants takes into consideration Asterias’ recent announcement of positive interim efficacy results from its ongoing SCiStar Phase 1/2a clinical trial that showed additional motor function improvement at 6 months and 9 months following administration of 10 million AST-OPC1 cells in patients with complete cervical spinal cord injuries (AIS-A patients).  Further data will become available in the third quarter of 2017 evaluating 12-month safety and efficacy results for this AIS-A 10 million cell cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts.

“We were excited by the recent positive read-out on the AIS-A 10 million cell cohort in our SCiStar clinical trial.  This data reinforced the very positive motor function improvements observed in complete cervical spinal cord injury patients announced in September 2016,” said Steve Cartt, Chief Executive Officer of Asterias. “We hope to see continued positive results when we report additional data read-outs later this year.  In addition, we expect to make significant progress during 2017 as we complete enrollment in the SCiStar clinical trial and engage in discussions with the FDA to design a new AST-OPC1 randomized-controlled trial that we expect to commence in early 2018.”

The company is extending the expiration date of warrants to purchase up to an aggregate of 3,329,035 shares of the company’s Series A common stock, par value $0.0001 per share. The expiration date for these warrants, which otherwise would have expired on February 15, 2017, has been extended to 5:00 p.m. New York City time on September 29, 2017.  The company is also extending the expiration date of the warrants to purchase up to an aggregate of 409,152 shares of common stock held by Romulus Films Ltd.  The expiration date for the warrants held by Romulus has also been extended to 5:00 p.m. New York City time on September 29, 2017.

In addition, Asterias provided an update on its cash position. As of December 31, 2016, the company’s cash and cash equivalents totaled $19.8 million (unaudited) and its cash, cash equivalents and available-for-sale securities totaled $35.1 million (unaudited).

“Asterias’ cash position at the end of 2016 is significantly improved from the same time last year, and positions us to further advance our development programs through key milestones for the company, including completing enrollment of the SCiStar study, during 2017,” said Ryan Chavez, Chief Financial Officer. “Management believes the company’s cash, cash equivalents and available-for-sale securities will be sufficient to fund operations through at least the first quarter of 2018.”                                                            

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.

AST-VAC1 (antigen-presenting autologous dendritic cells) is undergoing continuing development by Asterias based on promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML) and completing a successful end-of-Phase 2 meeting with the FDA. The company is currently focused on streamlining and modernizing the manufacturing process for AST-VAC1 in advance of a planned initiation of a Phase 2b study designed to set the registration pathway. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic immunotherapy. The company’s research partner, Cancer Research UK, plans to begin a Phase 1/2a clinical trial of AST-VAC2 in non-small cell lung cancer in the second quarter of 2017. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.